Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etoposide toniribate - Mundipharma

Next Previous
Drug Profile

Etoposide toniribate - Mundipharma

Alternative Names: CAP-7.1

Latest Information Update: 31 Jul 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute for Medical Immunology Charite - Universitatsmedizin Berlin
  • Developer CellAct Pharma; Mundipharma EDO
  • Class Antineoplastics; Naphthols; Small molecules
  • Mechanism of Action Carbonic anhydrase stimulants; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Biliary cancer
  • No development reported Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 31 Jul 2019 Etoposide toniribate is still in phase II trials for Biliary cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany
  • 31 Jul 2019 No development reported - Phase-II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV)
  • 31 Jul 2019 No development reported - Phase-II for Small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top